FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125233997> ?p ?o ?g. }

• W2125233997 endingPage "1604" @default.
• W2125233997 startingPage "1595" @default.
• W2125233997 abstract "Purpose Minimal residual disease (MRD) is an important prognostic factor in adults with acute lymphoblastic leukemia (ALL) and may be used for treatment decisions. The Programa Español de Tratamientos en Hematología (PETHEMA) ALL-AR-03 trial (Treatment of High Risk Adult Acute Lymphoblastic Leukemia [LAL-AR/2003]) assigned adolescent and adult patients (age 15 to 60 years) with high-risk ALL (HR-ALL) without the Philadelphia (Ph) chromosome to chemotherapy or to allogeneic hematopoietic stem-cell transplantation (allo-HSCT) according to early cytologic response (day 14) and flow-MRD level after consolidation. Patients and Methods Patients with good early cytologic response (< 10% blasts in bone marrow at day 14 of induction) and a flow-MRD level less than 5 × 10 −4 at the end of consolidation were assigned to delayed consolidation and maintenance therapy, and allo-HSCT was scheduled in patients with poor early cytologic response or flow-MRD level ≥ 5 × 10 −4 . Results Complete remission was attained in 282 (87%) of 326 patients, and 179 (76%) of 236 patients who completed early consolidation were assigned by intention-to treat to receive allo-HSCT (71) or chemotherapy (108). Five-year disease-free survival (DFS) and overall survival (OS) probabilities were 37% and 35% for the whole series, 32% and 37% for patients assigned to allo-HSCT, and 55% and 59% for those assigned to chemotherapy. Multivariable analysis showed poor MRD clearance (≥ 1 × 10 −3 after induction and ≥ 5 × 10 −4 after early consolidation) as the only prognostic factor for DFS and OS. Conclusion Prognosis for Ph-negative HR-ALL in adolescents and adults with good early response to induction and low flow-MRD levels after consolidation is quite favorable when allo-HSCT is avoided. In this study, the pattern of MRD clearance was the only prognostic factor for DFS and OS." @default.
• W2125233997 created "2016-06-24" @default.
• W2125233997 creator A5003682435 @default.
• W2125233997 creator A5004401859 @default.
• W2125233997 creator A5006173909 @default.
• W2125233997 creator A5008564951 @default.
• W2125233997 creator A5011772396 @default.
• W2125233997 creator A5014009900 @default.
• W2125233997 creator A5014775908 @default.
• W2125233997 creator A5016510706 @default.
• W2125233997 creator A5017225753 @default.
• W2125233997 creator A5027815550 @default.
• W2125233997 creator A5028729135 @default.
• W2125233997 creator A5029238392 @default.
• W2125233997 creator A5033227605 @default.
• W2125233997 creator A5040138933 @default.
• W2125233997 creator A5041309879 @default.
• W2125233997 creator A5054952877 @default.
• W2125233997 creator A5058799782 @default.
• W2125233997 creator A5063931881 @default.
• W2125233997 creator A5069030466 @default.
• W2125233997 creator A5069688230 @default.
• W2125233997 creator A5074130459 @default.
• W2125233997 creator A5080835213 @default.
• W2125233997 creator A5082351468 @default.
• W2125233997 creator A5084354003 @default.
• W2125233997 creator A5089188528 @default.
• W2125233997 date "2014-05-20" @default.
• W2125233997 modified "2023-10-18" @default.
• W2125233997 title "Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial" @default.
• W2125233997 cites W1685744202 @default.
• W2125233997 cites W1967348190 @default.
• W2125233997 cites W1969912329 @default.
• W2125233997 cites W1977921909 @default.
• W2125233997 cites W1981648274 @default.
• W2125233997 cites W1987641123 @default.
• W2125233997 cites W1998660089 @default.
• W2125233997 cites W2001772352 @default.
• W2125233997 cites W2003563966 @default.
• W2125233997 cites W2026177698 @default.
• W2125233997 cites W2029650920 @default.
• W2125233997 cites W2035343180 @default.
• W2125233997 cites W2038414910 @default.
• W2125233997 cites W2039642633 @default.
• W2125233997 cites W2050152294 @default.
• W2125233997 cites W2053749592 @default.
• W2125233997 cites W2058885398 @default.
• W2125233997 cites W2067098914 @default.
• W2125233997 cites W2081127271 @default.
• W2125233997 cites W2090630520 @default.
• W2125233997 cites W2090845094 @default.
• W2125233997 cites W2109388187 @default.
• W2125233997 cites W2118241155 @default.
• W2125233997 cites W2147572934 @default.
• W2125233997 cites W2148631711 @default.
• W2125233997 cites W2163926478 @default.
• W2125233997 cites W2416430600 @default.
• W2125233997 cites W4293241248 @default.
• W2125233997 cites W4298434897 @default.
• W2125233997 cites W4376542656 @default.
• W2125233997 doi "https://doi.org/10.1200/jco.2013.52.2425" @default.
• W2125233997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24752047" @default.
• W2125233997 hasPublicationYear "2014" @default.
• W2125233997 type Work @default.
• W2125233997 sameAs 2125233997 @default.
• W2125233997 citedByCount "210" @default.
• W2125233997 countsByYear W21252339972014 @default.
• W2125233997 countsByYear W21252339972015 @default.
• W2125233997 countsByYear W21252339972016 @default.
• W2125233997 countsByYear W21252339972017 @default.
• W2125233997 countsByYear W21252339972018 @default.
• W2125233997 countsByYear W21252339972019 @default.
• W2125233997 countsByYear W21252339972020 @default.
• W2125233997 countsByYear W21252339972021 @default.
• W2125233997 countsByYear W21252339972022 @default.
• W2125233997 countsByYear W21252339972023 @default.
• W2125233997 crossrefType "journal-article" @default.
• W2125233997 hasAuthorship W2125233997A5003682435 @default.
• W2125233997 hasAuthorship W2125233997A5004401859 @default.
• W2125233997 hasAuthorship W2125233997A5006173909 @default.
• W2125233997 hasAuthorship W2125233997A5008564951 @default.
• W2125233997 hasAuthorship W2125233997A5011772396 @default.
• W2125233997 hasAuthorship W2125233997A5014009900 @default.
• W2125233997 hasAuthorship W2125233997A5014775908 @default.
• W2125233997 hasAuthorship W2125233997A5016510706 @default.
• W2125233997 hasAuthorship W2125233997A5017225753 @default.
• W2125233997 hasAuthorship W2125233997A5027815550 @default.
• W2125233997 hasAuthorship W2125233997A5028729135 @default.
• W2125233997 hasAuthorship W2125233997A5029238392 @default.
• W2125233997 hasAuthorship W2125233997A5033227605 @default.
• W2125233997 hasAuthorship W2125233997A5040138933 @default.
• W2125233997 hasAuthorship W2125233997A5041309879 @default.
• W2125233997 hasAuthorship W2125233997A5054952877 @default.
• W2125233997 hasAuthorship W2125233997A5058799782 @default.
• W2125233997 hasAuthorship W2125233997A5063931881 @default.
• W2125233997 hasAuthorship W2125233997A5069030466 @default.
• W2125233997 hasAuthorship W2125233997A5069688230 @default.
• W2125233997 hasAuthorship W2125233997A5074130459 @default.

• next